



- (51) **International Patent Classification:**
C12N 7/02 (2006.01) C12N 7/00 (2006.01)
- (21) **International Application Number:**
PCT/IB2024/053862
- (22) **International Filing Date:**
19 April 2024 (19.04.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/461,216 21 April 2023 (21.04.2023) US
- (71) **Applicant: NATIONAL RESEARCH COUNCIL OF CANADA** [CA/CA]; 1200 Montreal Road, Ottawa, Ontario K1A 0R6 (CA).
- (72) **Inventors: TRAN, Hue;** c/o Oncolytics Biotech Inc., 1167 Kensington Crescent NW, Suite 210, Calgary, Alberta T2N 1X7 (CA). **COFFEY, Matthew;** c/o Oncolytics Biotech Inc., 1167 Kensington Crescent NW, Suite 210, Calgary, Alberta T2N 1X7 (CA). **HAGERMAN, Allison;**

c/o Oncolytics Biotech Inc., 1167 Kensington Crescent NW, Suite 210, Calgary, Alberta T2N 1X7 (CA). **VOYER, Robert;** 960 50e avenue, Lachine, Québec H8T 2V1 (CA). **TIWARI, Krishna Raj;** 310-85 Brittany Avenue, Mont-Royal, Québec H3P 1A5 (CA). **LATAWA, Jyoti;** Apt#310 85 Brittany Avenue, Mont-Royal, Québec H3P 1A5 (CA). **PATEL, Mehul;** 27 Rue Capri, Dollard Des Ormeaux, Québec H9B 2G3 (CA). **MATTE, Allan;** 132 Manuel Drive, Dollard Des Ormeaux, Québec H9B 2B4 (CA).

- (74) **Agent: SMITH, Jessica et al.;** 1200 Montreal Road, Ottawa, Ontario K1A 0R6 (CA).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) **Title: IMPROVEMENT IN VIRAL EXTRACTION FROM CELL CULTURE**




FIG. 5

- (57) **Abstract:** Provided herein are methods of producing virus from a culture of host cells. The methods include providing a culture of host cells which has been infected by the virus; contacting the host cells with a first buffer comprising a detergent and incubating the host cells in the presence of the first buffer for a first period of time thereby producing a cell lysate; contacting the cell lysate with a second buffer comprising an endonuclease for a second period of time to degrade the host cell nucleic acids; and collecting the virus.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*